research The therapeutic use of androgens in women
This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.
Search
forResearch
5 / 1000+ resultsresearch Therapeutic Androgen Receptor Ligands
Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
research Therapeutic Strategies to Target the Androgen Receptor
This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.
research THERAPEUTIC HOTLINE: Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics
This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.
research Chapter 23. Therapeutic Control of Androgen Action
This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.
Community Join
5 / 1000+ resultscommunity Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community NMN Promotes Cell Proliferation and Hair Growth by Reducing Oxidative Stress
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Learn
2 / 12 results- What is GT20029 and how does it work as a topical anti-androgen for hair loss? GT20029 is an investigational topical androgen-receptor degrader. One 12-week Phase II trial in 180 Chinese men found two of four regimens beat placebo on hair count; it is not approved or available.
- Who is spironolactone used for in androgen-related hair thinning, and who should avoid it? Studies of spironolactone for hair loss are mostly in adult women; its use is off-label, it is avoided in pregnancy and generally not used in men, and the US label advises potassium checks (DailyMed, Aldactone).
learn GT20029
learn Spironolactone
Clinics
2 / 10 results
Experts
— no results